 |
| Johanna Lister |
My name is Johanna Lister and I am in the first year of my
PhD in HEDS. Before embarking on my PhD, I have worked as a Health Analyst in
various organisations. These range from public sector organisations, such as the
Department of Health in London, to private sector companies, like my current
employer Certara. I am doing my PhD as a distance student from South Germany on
a part-time basis, making it even more of a challenge than it already is!
The topic of my PhD is the identification of evidence for
key parameters for economic models of health technologies. Over the last 10
years I have been leading complex engagements with pharmaceutical companies
that include evidence generation for Health Technology Assessments (HTAs)
around the world, with specific focus on health economic models. I have noticed
that it is difficult to distribute research efforts so that all HTA
requirements are met for several HTA agencies and for several purposes
(systematic literature review, indirect treatment comparison, economic model,
etc.) with a finite time and budget. I applied to study at Sheffield
specifically because I found the most interesting research on the topic to be
conducted there. Studying remotely is challenging, but the quality of
supervision and the faculty more than makes up for it!
Title of PhD: Identification of evidence for key parameters for decision analytic models to evaluate cost-effectiveness of health care technologies
My research interests include:
· Methods used in the pharmaceutical manufacturers submissions within Health Technology Assessment agencies appraisal processes.
· Retrieval of evidence for decision analytic models of cost-effectiveness
Key publications
- Amzal B, Fu S, Meng J, Lister J, Karcher H (2017) Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLOS ONE 12(9): e0184423.
- Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultayaev D, Lister J, Drake M. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Health Econ (2016) 17: 911.
- Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de Castro Carpeno J, Crott R, Kleman M & Ngoh C. Simulation and comparison of progression-free survival (PFS) among patients with non-squamous non-small cell lung cancer (NSCLC) recieving sequential therapy. Expert Rev. Anticancer Ther. Early online, 1–8 (2014).
- Lee E, Revil C, Ngoh C, Lister J, Kwon JM, Park MH, et al. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther. 2012;34(6):1408-19.
- Lister J , Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain. Clinicoecon Outcomes Res. 2012 2012;4.
- Ahn M, Tsai C, Hsia T, Wright E, Chang J, Kim H, Kim J, Kang J, Kim S, Bae E, Kang M, Lister J, Walzer S. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. Asia Pac J Clin Oncol. 2011;7 Suppl 2:22-33.
Supervisors
- Lead Supervisor: Suzy Paisley
- Second Supervisor: Eva Kaltenthaler
- Third supervisor: Paul Tappenden
https://www.linkedin.com/in/johanna-lister-6364975/